# Revised artifact

## Recommendation
Do not treat caution as free. Under partial market data, the right recommendation is a bounded pricing decision that explicitly compares two risks: the cost of a wrong pricing move and the cost of delayed action. The default path should still be a staged pricing change only when the expected downside of broad repricing is higher than the expected cost of waiting. If available internal signals already suggest severe mispricing, the company should move faster than a narrow test.

## Decision Logic
Use a simple decision rule:

- Choose `staged rollout` when uncertainty is high, reversal is feasible, and the likely cost of a broad mistake exceeds the likely cost of one review-cycle delay.
- Choose `accelerated broader change` when internal evidence already shows strong mispricing signals, such as persistent discount pressure, materially low win rates attributable to price, unusually strong expansion at current pricing, or repeated prospect loss due to packaging mismatch.
- Choose `hold current pricing briefly while collecting evidence` only if the business cannot instrument outcomes or operationally support even a controlled change.

This reframes the recommendation: a staged move is not inherently safest; it is preferable only when it dominates the alternatives on expected regret.

## Decision Frame
The decision is not simply `small test` versus `full repricing`. It is a three-way choice among:

- `Preferred under high uncertainty`: constrained, reversible pricing or packaging test with explicit success and rollback thresholds.
- `Preferred under strong internal mispricing signals`: faster and broader pricing action, still with monitoring and exception handling.
- `Least preferred`: passive continuation of current pricing without a dated evidence plan, because inaction also carries revenue, pipeline, and competitive costs.

Given the packet, there is not enough evidence to justify full repricing. But there is also not enough evidence to assume the status quo is neutral. The usable recommendation is therefore: make the smallest decision that still reflects the likely cost of inaction, and require the team to state that tradeoff explicitly before launch.

## Unknowns & Evidence Gaps
Critical missing inputs:

- Segment-level willingness to pay.
- Current win/loss reasons tied to price and packaging.
- Competitor pricing and packaging comparables.
- Gross retention and expansion sensitivity to price changes.
- Sales discounting behavior and realized price variance.
- Evidence on cost of inaction: daily revenue leakage, pipeline suppression, or margin loss under current pricing.
- Likelihood that a narrow test would be biased or non-generalizable.

Because these gaps remain unresolved, the team should not present conservatism as the default. It should present an explicit uncertainty tradeoff.

## Pass/Fail Readiness
`Pass` if all of the following are true:

- The team has compared expected cost of action versus expected cost of delay.
- The rollout scope matches the level of evidence and reversibility.
- Success metrics, rollback thresholds, and review timing are pre-specified.
- Baseline metrics exist for conversion, retention, expansion, discounting, and sales-cycle effects.
- Commercial exception handling and customer communication are prepared.

`Fail` if any of the following are true:

- The recommendation assumes the current price is a neutral baseline.
- The proposal defaults to caution without quantifying delay cost.
- The planned test is too narrow to inform the next decision and no mitigation for selection bias is defined.
- Leadership expects high-confidence optimization from partial evidence.

Current readiness: `Pass with conditions for a bounded decision process`, `Fail for unsupported broad repricing`, and `Fail for passive status-quo maintenance without a dated evidence plan`.

## Recommended Next Artifact
Create a pricing decision brief, not just a pricing experiment brief. It should include:

- current-state mispricing hypotheses
- estimated cost of inaction over the next decision window
- expected downside of a wrong pricing move
- decision rule for staged rollout versus broader action versus temporary hold
- target segment or package, if testing is chosen
- metrics, thresholds, and bias risks
- evidence plan for competitor checks and willingness-to-pay follow-up

This is the next artifact because the core missing step is not only experiment design; it is explicit comparison of action risk versus delay risk.

## Decision Frame
Recommend a bounded pricing decision that explicitly weighs the expected cost of action against the expected cost of delay. Default to a staged, reversible change only when the downside of a broader move is more credible than the cost of waiting one review cycle.

## Unknowns & Evidence Gaps
The packet lacks direct evidence on elasticity, competitor benchmarks, segment differences, and the magnitude of current mispricing. It also lacks any quantified estimate of the cost of maintaining current pricing during the learning period.

## Pass/Fail Readiness
The strategy is decision-useful only if the team can state why its chosen level of speed and scope is justified relative to both action risk and inaction risk. Without that comparison, the recommendation remains under-specified.

## Recommended Next Artifact
A pricing decision brief with explicit action-versus-delay tradeoffs, followed by an experiment brief only if the decision path is a staged rollout.
